Practical guidance for implementing predictive biomarkers into early phase clinical studies

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Marton, Matthew J ^a   Weiner, Russell ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; FORMALDEHYDE; PARAFFIN; RNA;

ACCURACY; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL LABORATORY; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COST; DEVICE APPROVAL; DISEASE PREDISPOSITION; FLOW CYTOMETRY; FOOD AND DRUG ADMINISTRATION; GOOD LABORATORY PRACTICE; HUMAN; IMMUNOHISTOCHEMISTRY; LAW; LIMIT OF DETECTION; MEDICAID; MEDICARE; NUCLEIC ACID ANALYSIS; PATENT; PATIENT SELECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRESERVATION; PURIFICATION; QUALITY CONTROL; QUALITY CONTROL PROCEDURES; RELIABILITY; RNA SEQUENCE; SAMPLING; SINGLE NUCLEOTIDE POLYMORPHISM; TEMPERATURE; TURNAROUND TIME; DIAGNOSTIC TEST; DRUG DEVELOPMENT; HIGH THROUGHPUT SEQUENCING; METHODOLOGY; REVIEW; STANDARD; TRANSLATIONAL RESEARCH; UNITED STATES; VALIDATION STUDY;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC TESTS, ROUTINE; DRUG DISCOVERY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84887450214     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/891391     Document Type: Article

References (17)

1. Nohaile M., The biomarker is not the end. Drug Discovery Today 2011 16 19-20 878 883 2-s2.0-80054004797 10.1016/j.drudis.2011.08.011
2. Xie R., Chung J.-Y., Ylaya K., Williams R. L., Guerrero N., Nakatsuka N., Badie C., Hewitt S. M., Factors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sections. Journal of Histochemistry and Cytochemistry 2011 59 4 356 365 2-s2.0-79955680588 10.1369/0022155411398488
3. The cobas 4800 BRAF V600 Mutation Test Product Insert, 2012, http://www.accessdata.fda.gov/cdrh-docs/pdf11/P110020c.pdf
4. Maak M., Simon I., Nitsche U., Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Annals of Surgery 2013 257 6 1053 1058 10.1097/SLA.0b013e31827c1180
5. Eberhard D. A., Giaccone G., Johnson B. E., Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting. Journal of Clinical Oncology 2008 26 6 983 994 2-s2.0-39749144726 10.1200/JCO.2007.12.9858 (Pubitemid 351398092)
6. Olson W. C., Smolkin M. E., Farris E. M., Fink R. J., Czarkowski A. R., Fink J. H., Chianese-Bullock K. A., Slingluff C. L. Jr., Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. Journal of Translational Medicine 2011 9, article 26 2-s2.0-79952320073 10.1186/1479-5876-9-26
7. Duenwald S., Zhou M., Wang Y., Lejnine S., Kulkarni A., Graves J., Smith R., Castle J., Tokiwa G., Fine B., Dai H., Fare T., Marton M., Development of a microarray platform for FFPET profiling: application to the classification of human tumors. Journal of Translational Medicine 2009 7, article 65 2-s2.0-70249124197 10.1186/1479-5876-7-65
8. FDA News Release P07-13, FDA clears breast cancer specific molecular prognostic test. News & Events, February 2007, http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2007/ucm108836.htm
9. FDA News Release, FDA clears test that helps identify type of cancer in tumor sample. News & Events, February 2007, http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2008/ucm116931.htm
10. FDA News Release Approval of Kras test, FDA approves genetic test to help some colon cancer patients, physicians considering Erbitux therapy. News & Events, July 2012, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm310899.htm
11. Gargis A. S., Kalman L., Berry M. W., Assuring the quality of next-generation sequencing in clinical laboratory practice. Nature Biotechnology 2012 30 11 1033 1036 10.1038/nbt.2403
12. Perez E. A., Suman V. J., Davidson N. E., Martino S., Kaufman P. A., Lingle W. L., Flynn P. J., Ingle J. N., Visscher D., Jenkins R. B., HER2 testing by local, central, and reference laboratories in specimens from the north central cancer treatment group N9831 intergroup adjuvant trial. Journal of Clinical Oncology 2006 24 19 3032 3038 2-s2.0-33745986327 10.1200/JCO.2005.03. 4744 (Pubitemid 46638937)
13. André T., Blons H., Mabro M., Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Annals of Oncology 2013 24 2 412 419 10.1093/annonc/mds465
14. Bellon E., Ligtenberg M. J. L., Tejpar S., Cox K., de Hertogh G., de Stricker K., Edsjö A., Gorgoulis V., Höfler G., Jung A., Kotsinas A., Laurent-Puig P., López-Ríos F., Hansen T. P., Rouleau E., Vandenberghe P., van Krieken J. J. M., Dequeker E., External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011 16 4 467 478 2-s2.0-79952698311 10.1634/theoncologist.2010-0429
15. FDA Draft Guidance for Industry and FDA Staff, Commercially Distributed in Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions. June 2011
16. FDA Draft Guidance for Industry, Clinical Laboratories, and FDA Staff. In Vitro Diagnostic Multivariate Index Assays, July 2007
17. FDA Draft Guidance for Industry and FDA Staff. In Vitro Companion Diagnostic Devices, July 2011